全文获取类型
收费全文 | 225篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 4篇 |
临床医学 | 4篇 |
内科学 | 192篇 |
神经病学 | 28篇 |
外科学 | 2篇 |
综合类 | 3篇 |
预防医学 | 1篇 |
药学 | 2篇 |
中国医学 | 1篇 |
肿瘤学 | 6篇 |
出版年
2023年 | 7篇 |
2022年 | 2篇 |
2021年 | 14篇 |
2020年 | 6篇 |
2019年 | 11篇 |
2018年 | 10篇 |
2017年 | 7篇 |
2016年 | 6篇 |
2015年 | 9篇 |
2014年 | 13篇 |
2013年 | 24篇 |
2012年 | 12篇 |
2011年 | 9篇 |
2010年 | 7篇 |
2009年 | 9篇 |
2008年 | 9篇 |
2007年 | 17篇 |
2006年 | 16篇 |
2005年 | 21篇 |
2004年 | 12篇 |
2003年 | 4篇 |
2002年 | 7篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1993年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1976年 | 3篇 |
1972年 | 2篇 |
排序方式: 共有244条查询结果,搜索用时 15 毫秒
1.
2.
3.
Mario Iannaccone Mohamed Abdirashid Umberto Annone Gaëlle Saint‐Hilary Pascal Meier Alaide Chieffo Sl Chen Carlo di Mario Federico Conrotto Pierluigi Omed Antonio Montefusco Michele De Benedictis Sara Rettegno Baldassare Doronzo Mauro Gasparini Mauro Rinaldi Maurizio D'Amico Fabrizio D'Ascenzo 《Catheterization and cardiovascular interventions》2020,95(7):1259-1266
4.
Nicolas M. Van Mieghem Didier Tchetche Alaide Chieffo Nicolas Dumonteil David Messika-Zeitoun Robert M.A. van der Boon Olivier Vahdat Gill L. Buchanan Bertrand Marcheix Dominique Himbert Patrick W. Serruys Jean Fajadet Antonio Colombo Didier Carrié Alec Vahanian Peter P.T. de Jaegere 《The American journal of cardiology》2012,110(9):1361-1367
5.
6.
Giuseppe Tarantini MD Giulia Masiero MD Francesco Burzotta MD Vittorio Pazzanese MD Carlo Briguori MD Carlo Trani MD Tommaso Piva MD Federico De Marco MD Maurizio Di Biasi MD Paolo Pagnotta MD Marco Mojoli MD Gavino Casu MD Gennaro Giustino MD Giulia Lorenzoni PhD Matteo Montorfano MD Marco B. Ancona MD Federico Pappalardo MD Alaide Chieffo MD IMPella Mechanical Circulatory Support Device in Italy Registry authors 《Catheterization and cardiovascular interventions》2021,98(2):E222-E234
7.
Robert M.A. van der Boon Bertrand Marcheix Didier Tchetche Alaide Chieffo Nicolas M. Van Mieghem Nicolas Dumonteil Olivier Vahdat Francesco Maisano Patrick W. Serruys A. Pieter Kappetein Jean Fajadet Antonio Colombo Didier Carrié Ron T. van Domburg Peter P.T. de Jaegere 《The Annals of thoracic surgery》2014
8.
9.
Gill Louise Buchanan Alaide Chieffo Emanuele Meliga Roxana Mehran Seung-Jung Park Yoshinobu Onuma Piera Capranzano Marco Valgimigli Inga Narbute Raj R. Makkar Igor F. Palacios Young-Hak Kim Piotr P. Buszman Tarun Chakravarty Imad Sheiban Christoph Naber Ronan Margey Arvind Agnihotri Sebastiano Marra Davide Capodanno Victoria Allgar Martin B. Leon Jeffrey W. Moses Jean Fajadet Thierry Lefevre Marie-Claude Morice Andrejs Erglis Corrado Tamburino Ottavio Alfieri Patrick W. Serruys Antonio Colombo 《The American journal of cardiology》2014
10.
David Jochheim Marco Barbanti Giuliana Capretti Giulio G. Stefanini Alexander Hapfelmeier Magda Zadrozny Moritz Baquet Julius Fischer Hans Theiss Denise Todaro Alaide Chieffo Patrizia Presbitero Antonio Colombo Steffen Massberg Corrado Tamburino Julinda Mehilli 《JACC: Cardiovascular Interventions》2019,12(16):1566-1576
ObjectivesThe purpose of the study was to investigate the impact of oral anticoagulation (OAC) type on clinical outcomes 1 year after transcatheter aortic valve replacement (TAVR).BackgroundNon–vitamin K oral anticoagulants (NOACs) are superior to vitamin K antagonists (VKAs) in nonvalvular atrial fibrillation (AF), while their comparative performance among patients in need of OAC undergoing TAVR is underinvestigated.MethodsThe study enrolled 962 consecutive patients who underwent TAVR in 4 tertiary European centers and were discharged on either NOACs (n = 326) or VKAs (n = 636). By using propensity scores for inverse probability of treatment weighting (IPTW), the comparison of treatment groups was adjusted to correct for potential confounding.ResultsMean age and Society of Thoracic Surgeons score of the population were 81.3 ± 6.3 years and 4.5% (interquartile range: 3.0% to 7.3%); 52.5% were women and a balloon-expandable valve was used in 62.7% of cases. The primary outcome of interest, combined incidence of all-cause mortality, myocardial infarction, and any cerebrovascular event at 1-year after TAVR, was 21.2% with NOACs versus 15.0% with VKAs (hazard ratio [HR]: 1.44; 95% confidence interval [CI]: 1.00 to 2.07; p = 0.050, IPTW-adjusted). The 1-year incidence of any Bleeding Academic Research Consortium bleeds and all-cause mortality were comparable between the NOAC and VKA groups, 33.9% versus 34.1% (HR: 0.97; 95% CI: 0.74 to 1.26; p = 0.838, IPTW-adjusted) and 16.5% versus 12.2% (HR: 1.36; 95% CI: 0.90 to 2.06; p = 0.136, IPTW-adjusted), respectively.ConclusionsChronic use of both NOACs and VKAs among patients in need of OAC after TAVR are comparable regarding 1-year bleeding risk. The higher ischemic event rate observed with NOACs needs to be evaluated in large randomized trials. 相似文献